講演・口頭発表等 - 平川　晃弘

分割表示  199 件中 1 - 20 件目  ／  全件表示 >>

  1. 児玉 祐一, 西 眞範, 佐藤 篤, 今村 知世, 出口 隆生, 平川 晃弘, 清河 信敬, 大木 健太郎, 嶋 晴子, 加藤 啓輔, 加藤 元博, 河崎 裕英, 坂口 大俊, 平松 英文, 後藤 裕明, 山本 将平, 伊藤 正樹, 谷澤 明彦, 湯坐 有希, 齋藤 明子, 小川 千登世, 多賀 崇, 足立 壯一, 嶋田 博之. 小児再発・難治フィラデルフィア染色体陽性白血病に対するポナチニブ安全性確認試験. 日本血液学会学術集会 2023.10.01

  2. 大森 寛行, 川瀬 世史明, 水上 拓也, 谷垣 徹, 平田 哲夫, 大久保 宗則, 神谷 宏樹, 平川 晃弘, 川崎 雅規, 近藤 武, 鈴木 孝彦, 松尾 仁司. 心筋虚血とプラーク診断におけるAI画像診断　Virtual FFRとAI. 日本心血管インターベンション治療学会抄録集 2023.08.01

  3. Arai H, Sugimoto T, Akatsu H, Doi T, Fujiwara Y, Hirakawa A, Kinoshita F, Kuzuya M, Lee S, Matsuo K, Michikawa M, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Suzuki H, Takechi H, Takeda S, Umegaki H, Wakayama S, Sakurai T, J-MINT study group. The Japan-multimodal intervention trial for prevention of dementia (J-MINT): a multi-center, randomized, 18-month controlled trial. AAIC 2023 2023.07.16

  4. 田中 一, 布川 裕規, 山本 浩平, 谷本 幸介, 竹本 暁, 蓮見 壽史, 平川 晃弘, 石川 雄大, 福田 翔平, 早稲田 悠馬, 吉田 宗一郎, 横山 みなと, 藤井 靖久. 淡明細胞型腎細胞癌における腎実質浸潤/進展の意義　予後への影響と遺伝学的背景(Renal parenchymal infiltration or micronodular spread in clear cell renal cell carcinoma: prognostic impact and genomic backgrounds). 日本泌尿器科学会総会 2023.04.01

  5. Tsuchiya K, Nagahori M, Hanazawa R, Sasaki S, Sato H, Hirakawa A, Anzai T, Takahashi K, Kobayashi Y, Hibiya S, Takenaka K, Watanabe M. Serial daily recording of patient-reported outcomes (PRO2) might predict treatment change in the patients with ulcerative colitis. ECCO 2023 2023.03.01

  6. Uemura Y, Yamamoto M, Ishimura M, Kanegane H, Sawada A, Hirakawa A, Imadome K, Yoshimori M, Nagata M, Shimizu N, Koike R, Arai A.. Phase II Study of a JAK1/2 Inhibitor Ruxolitinib for Systemic Chronic Active Epstein-Barr Virus Disease: An Investigator-Initiated Trial. . ASH 2022 2022.12.10

  7. Sato H, Sasaki M, Hirakawa A. Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents.. 2022 WNAR Annual Meeting 2022.06.13

  8. Sato H, Sasaki M, Hirakawa A.. Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents.. 2022 WNAR Annual Meeting 2022.06.13

  9. Ikeda S, Kudo R, Yamashita, Y, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Tateishi U, Hirakawa A, Akita H, Matsubara H, Nishihara H, Ishioka C, Sueoka-Aragane N, Muto M, Toyooka S. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. . Annual Meeting, American Society of Clinical Oncology 2022.06.05

  10. Arakawa A, Ozawa H, Hirakawa A, Sadachi R, Hoshina Y, Tomatsuri S, Saito Y, Ando R, Terashima K, Nakamura K, Ogawa C. A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.. Annual Meeting, American Society of Clinical Oncology 2022.06.03

  11. Kojima Y, Shimizu T, Yonemori K, Koyama T, Matsui N, Kamikura M, Tomatsuri S, Sumiyoshi Okuma H, Shimoi T, Noguchi E, Sudo K, Hirakawa A, Sadachi S, Okita N, Nakamura K, Yamamoto N, Fujiwara Y.. A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra- rare cancer with a highly life-threatening unmet needs（NCCH1806/MK004）. ESMO Congress 2021 2021.09.16

  12. Hasegawa K, Nishikawa T, Hirakawa A, Kawasaki M, Tomatsuri S, Nagasaka Y, Nakamura K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Yoshida H, Yonemori K. . Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE TRIAL, NCCH1615): A MULTICENTER, PHASE 2 CLINICAL TRIAL. . ESMO Congress 2021 2021.09.16

  13. Kudo R, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Akita H, Matsubara H, Nishihara H, Ishioka C, Aragane N, Muto M, Toyooka S,1 Tateishi U, Hirakawa A, Miyake S, Ikeda S.. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial). ASCO 2021.06.04

  14. Kawai A, Nishikawa T, Kawasaki M, Tomatsuri S, Okamura N, Ogawa G, Hirakawa A, Shibata T, Nakamura K, Kakunaga S, Tamura K, Ando M, Ozaki T, Ueda T, Yonemori K. . Efficacy and Safety of Nivolumab Monotherapy in Patients with Unresectable Clear Cell Sarcoma and Alveolar Soft Part Sarcoma (OSCAR t rial, NCCH1510): A Multicenter, Phase 2 Clinical Trial OSCAR.. CTOS 2020 Annual Meeting 2020.11.18

  15. Asano J, Hirakawa A.. An Empirical Bayesian Basket Trial Design Accounting for　Uncertainties of Homogeneity and Heterogeneity of Treatment Effect among Subpopulations. . ENAR 2020 Spring Meeting 2020.03.22

  16. Hirakawa A. An experience of data sharing utilization. 第16回DIA日本年会 2019.11.11

  17. Hirakawa A. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: application to basket trial data. 6th International Society of Biopharmaceutical Statistics 2019.08.26

  18. Hirakawa A. Single-pivotal basket trials for rare cancer development in Japan.. 2019 the Japanese Society of Medical Oncology Annual Meeting, 2019.07.19

  19. Hirakawa A. A clustering-based basket design. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

  20. Hirakawa A. . A clustering-based basket design.. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

< 前のページ - 次のページ >

このページの先頭へ▲